Compare PPSI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | PLUR |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 33.9M |
| IPO Year | 2008 | 2001 |
| Metric | PPSI | PLUR |
|---|---|---|
| Price | $3.27 | $3.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 128.9K | 4.7K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,627,000.00 | $1,336,000.00 |
| Revenue This Year | $2.71 | $97.38 |
| Revenue Next Year | $22.42 | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 20.75 | ★ 309.82 |
| 52 Week Low | $2.31 | $2.82 |
| 52 Week High | $5.70 | $6.10 |
| Indicator | PPSI | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 49.22 |
| Support Level | $3.11 | $3.22 |
| Resistance Level | $3.48 | $3.42 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 87.61 | 25.37 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.